DOI: http://dx.doi.org/10.18203/2349-3933.ijam20204515

Study of lipid profile in diabetic and non-diabetic chronic kidney disease patients on haemodialysis: a prospective comparative study from a sub Himalayan region in North India

Laxmi Nand, Rakesh Kumar, Kamal Kumar

Abstract


Background: Diabetes mellitus (DM) is a major cause of chronic kidney disease (CKD) leading to diabetic kidney disease (DKD). Several studies have observed lipid profile abnormalities in non-diabetic CKD patients with and without haemodialysis. Our study aims to reveal lipid profile abnormalities both in DKD and non-diabetic CKD patients on haemodialysis.

Methods: A prospective comparative study included 50 DKD and 50 non-diabetic CKD patients on haemodialysis and 50 controls after fulfilling the inclusion and exclusion criteria. The demographic and biochemical, including lipid profile parameters data of all subjects was collected and statistically analysed. p<0.05 was considered as statically significant.

Results: A total of 100 study patients, 50 DKD and 50 non-diabetic CKD patients, both on haemodialysis revealed significant dyslipidaemia when compared to controls. Total cholesterol in DKD patients on haemodialysis when compared to controls (177.5±80.5 versus 146.5±31.8 mg/dl) was significantly elevated (p=0.01). Low density lipoprotein (LDL) in DKD patients when compared to controls (94.1±43.3 versus 76.3±26.3 mg/dl) was also significantly elevated (p=0.01). Triglyceride levels in both DKD and non-diabetic CKD patients on haemodialysis in comparison to controls (213.8±182.1 and 169.2±132.3 versus 109.2±28.9 mg/dl respectively) were significantly elevated (p=0.0002 and p=0.003 respectively). Similarly, very low-density lipoprotein (VLDL) levels in both DKD and non-diabetic CKD patients were also significantly elevated when compared to controls (p=0.002 and p=0.003 respectively) whereas high density lipoprotein (HDL) was significantly reduced.

Conclusion: Both DKD and non-diabetic CKD patients on haemodialysis revealed significant dyslipidaemia, a major cause of increased risk for cardiovascular diseases necessitating early treatment with statins.


Keywords


Chronic kidney disease, Dyslipidaemia, Haemodialysis, Lipid profile, Cardiovascular diseases

Full Text:

PDF

References


Rajapurkar M, Dabhi M. Burden of disease – prevalence and incidence of renal disease in India. Clin Nephrol. 2011;74:9-12.

Madsen KM, Neilsen S, Tisher CC. Anatomy of the Kidney. In: Brenner BM, editors. Brenner and Rector's The Kidney. 7th edition. Philadelphia: Saunders. 2004;3-72.

Strong CG. Physiology of the human kidney. JAMA.1969;210(13):2399-400.

Persson F, Rossing P. Diagnosis of diabetic kidney disease: state of the art and future perspective. Kidney Int Suppl. 2018;8(1):2-7.

Lamb EJ, Tomson CRV, Roderick PJ. Estimating kidney function in adults using formulae. Ann Clin Biochem. 2005;42(5):321-45.

Agarwal R. Defining end-stage renal disease in clinical trials: A framework for adjudication. Nephrol Dial Transplant. 2016;31(6):864-7.

Kalmegh R, Idhol S. A retrospective study on chronic kidney disease and its etiological profile. J Med Res Prac. 2019;08(03):40-3.

Bricker NS, Bourgoignie J, Weber H, Schmidt RW, Slatopolsky E. Pathogenesis of the uremic state: a new perspective. Adv Nephrol Necker Hosp. 1972;2:263-76.

Alicic RZ, Rooney MT, Tuttle KR. Diabetic kidney disease: challenges, progress, and possibilities. Clin J Am Soc Nephrol. 2017;12(12):2032-45.

Gross JL, Azevedo MJ, Silveiro SP, Canani LH, Caramori ML, Zelmanovitz T. Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care. 2005;28(1):164-76.

Kuhar MB. Update on managing hypercholesterolemia. The new NCEP guidelines. AAOHN J. 2002;50(8):360-4.

Mehta V, Bhatt K. Lipids and its metabolism. J Cardiol Cardiovasc Ther. 2017;4(2):555-635.

Vaziri ND. Dyslipidemia of chronic renal failure : the nature, mechanisms, and potential consequences. Am J Physiol Renal Physiol. 2019;92868:262-72.

Kawanami D, Matoba K, Utsunomiya K. Dyslipidemia in diabetic nephropathy. Ren Replace Ther. 2016;2:1-9.

Rifai N, King ME, Sica DA. Effects of long-term haemodialysis on lipid, lipoprotein and apolipoprotein levels of black patients with chronic renal failure. Ann Clin Biochem. 1988;25(3):242-5.

Mekki K, Prost J, Remaoun M, Belleville J, Bouchenak M. Long term hemodialysis aggravates lipolytic activity reduction and very low density, low density lipoproteins composition in chronic renal failure patients. BMC CARDIOVASC DISOR. 2009;8:1-8.

Sharma H, Shah TJ, Gorasia JH, Baria DP. Lipid profile and lipoprotein(a) in chronic renal failure patients with and without hemodialysis. Int J Med Public Heal. 2012;2(4):28-31.

Raju DSSK, Lalita DL, Kiranmayi P. A study of lipid profile and lipid peroxidation in chronic kidney disease with special reference to hemodialysis. J Clin Res Bioeth. 2013;04(01):1-5.

Anjankar AP, Dharme PV, Anjankar VP. Study of comparative effect of hemodialysis and peritoneal dialysis on lipid profile of patients of chronic kidney disease. Asian J Biomed Pharmaceut Sci. 2014;04(36):30-4.

Herzog CA, Ma JZ, Collins AJ. Poor long term survival after acute myocardial infarction among patients on long-term dialysis is poor. N Engl J Med. 1998;339(12):799-805.

Karnik JA, Young BS, Lew NL, Herget M, Dubinsky C, Lazarus JM, et al. Cardiac arrest and sudden death in dialysis units. Kidney Int. 2001;60(1):350-7.

Ganta V, Yalamanchi RP, KC M, Sahu B, Raghvendar K, Anusha G, et al. A study of lipid profile in non-diabetic chronic kidney disease. Int J Adv Med. 2016;3(4):965-70.

Muntner P, He J, Astor BC, Folsom AR, Coresh J. Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: results from the atherosclerosis risk in communities study. J Am Soc Nephrol. 2005;16(2):529-38.

Harchaoui KEL, Visser ME, Kastelein JJP, Stroes ES, Thie GMD. Triglycerides and cardiovascular risk. Curr Cardiol Rev. 2009;5:216-22.

Bhagwat R, Joshi SP, Salgia P, Sepaha A. Lipid abnormalities in chronic renal failure. Indian J Clin Biochem. 1997;12(1):81-5.

Weiner DE, Sarnak MJ. Managing dyslipidemia in chronic kidney disease. J Gen Intern Med. 2004;19(10):1045-52.

Mikolasevic I, Zutelija M, Mavrinac V, Orlic L. Dyslipidemia in patients with chronic kidney disease: etiology and management. Int J Nephrol Renovasc Dis. 2017;10:35-45.

Rhee EJ, Kim HC, Kim JH, Lee EY, Kim BJ, Kim EM, et al. Guidelines for the management of dyslipidemia. Korean J Intern Med. 2019;34(4):723-71.

Kularia R, Sharma A, Acharya J. Dyslipidemia in chronic renal failure patients : a clinical study at tertiary care hospital , Bikaner. Int J Med Res Prof. 2018;4(3):147-9.

Wu L, Loaiza PF, Sauma J, Bogantes EH, Masis M. Classification of diabetic retinopathy and diabetic macular edema. World J Diabetes. 2013;4(6):290.

Maurya NK, Sengar NS, Arya P. Impact of hemodialysis on lipid profile among chronic renal failure patients (regular and non-regular haemodialysis). Pharma Innov J. 2018;7(4):363-5.

Phukan RR, Goswami RK. Unusual dyslipidemia in patients with chronic kidney diseases. J Clin Diagn Res. 2017;11(1):BC01-4.

Ahmad N, Agarwal S, Chauhan A, Khrime D, Varma A. A study of lipid profile in chronic renal failure patients in tertiary care hospital of Uttarakhand. Indian J Appl Res. 2018;1(1):51-2.

Morena M, Cristol JP, Dantoine T, Carbonneau MA, Descomps B, Canaud B. Protective effects of high-density lipoprotein against oxidative stress are impaired in haemodialysis patients. Nephrol Dial Transplant. 2000;15(3):389-95.

Prasannakumar M, Rajput R, Seshadri K, Talwalkar P, Agarwal P, Gokulnath G, et al. An observational, cross-sectional study to assess the prevalence of chronic kidney disease in type 2 diabetes patients in India (START -India). Indian J Endocrinol Metab. 2015;19(4):520-3.